Top Page
Osteopore Ltd.
(Sydney:OSX)
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
Osteopore Ltd. Business Overview & Revenue Model
Osteopore Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.81M | 2.22M | 1.78M | 1.40M | 2.23M |
| Gross Profit | 2.37M | 1.64M | 1.36M | 1.10M | 1.68M |
| EBITDA | -2.34M | -4.35M | -3.97M | -3.38M | -1.76M |
| Net Income | -3.35M | -4.87M | -4.22M | -3.93M | -2.69M |
Balance Sheet | |||||
| Total Assets | 3.13M | 3.34M | 3.62M | 6.01M | 10.25M |
| Cash, Cash Equivalents and Short-Term Investments | 638.50K | 1.16M | 2.16M | 5.13M | 9.03M |
| Total Debt | 1.33M | 1.09M | 74.18K | 106.71K | 453.99K |
| Total Liabilities | 2.83M | 2.91M | 1.51M | 633.40K | 1.25M |
| Stockholders Equity | 306.22K | 432.60K | 2.11M | 5.37M | 9.00M |
Cash Flow | |||||
| Free Cash Flow | -3.10M | -3.74M | -4.06M | -4.00M | -2.14M |
| Operating Cash Flow | -3.11M | -3.74M | -4.00M | -3.81M | -1.76M |
| Investing Cash Flow | -14.59K | -7.37K | -63.98K | -194.62K | -381.04K |
| Financing Cash Flow | 2.63M | 3.58M | 842.24K | -485.88K | 7.84M |
Osteopore Ltd. Technical Analysis
Osteopore Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | AU$210.47M | ― | -4.06% | ― | 20.36% | 64.81% | |
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% | |
51 Neutral | AU$292.54M | ― | -29.77% | ― | 6.07% | 59.09% | |
50 Neutral | AU$32.41M | ― | -81.30% | ― | -36.68% | 79.41% | |
47 Neutral | AU$12.07M | ― | -17.24% | ― | 34.47% | 41.83% | |
41 Neutral | AU$2.61M | ― | -907.51% | ― | 24.60% | 65.60% | |
40 Underperform | AU$105.25M | ― | -47.98% | ― | 700.00% | 26.88% |
Osteopore Ltd. Corporate Events
Osteopore Limited has initiated a clinical study in collaboration with Universiti Malaya to explore the efficacy of its polycaprolactone membrane compared to traditional collagen membranes in socket healing post-third molar surgery. This study, involving 18 patients, aims to address common post-operative issues such as pain and swelling, potentially improving periodontal health. The study’s outcome could position Osteopore’s product as a superior alternative due to its gradual degradation and enhanced barrier function, which may significantly impact the dental surgery field.
Osteopore Ltd. has successfully won tender bids to supply its orthopaedic products to two major public hospitals in Vietnam, marking a significant entry into the Vietnamese market. This development is expected to enhance Osteopore’s market position in the Asia Pacific region, particularly in the high-growth high tibial osteotomy and bone grafting markets, which are projected to grow significantly. The company plans to work with its distribution partner to finalize logistics and supply arrangements, aiming to capitalize on the growing demand driven by Vietnam’s aging population and increasing prevalence of orthopaedic conditions.
Osteopore Ltd. has announced the quotation of 30,120,481 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 31, 2025. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and offering new opportunities for stakeholders.
Osteopore Limited has reported a record quarterly revenue of AUD 835K for Q2 CY25, marking a 15% increase quarter-on-quarter and an 11% rise year-on-year. The company has also secured EU MDR clearance for its custom orthopaedic and cranial implants, which is expected to open new revenue streams and enhance its market presence in the European Union.
Osteopore Limited has reported significant progress following its Exclusive Distribution Agreement with Zimmer Biomet, a global medical technology leader. Over the first 12 months of the partnership, sales of Osteopore’s craniofacial products in Europe, Australia, and Hong Kong have tripled compared to the previous year. This growth highlights the company’s resilience in manufacturing and its ability to scale operations effectively. With recent European approval for custom-made cranioplasty implants, Osteopore anticipates increased market traction and plans to expand into new markets in collaboration with Zimmer Biomet.
Osteopore Ltd. has announced a change in the substantial holding of its shares, with Advance Opportunities Fund I reducing its stake from 11.63% to 9.07%. This shift in voting power reflects a sale of shares amounting to A$66,965.31, which may impact the company’s market dynamics and investor relations.
Osteopore Limited has announced that the Advance Opportunities Fund has ceased to be a substantial holder in the company. This change involves the indirect sale of shares valued at A$20,201.75, affecting 1,432,748 voting securities. The announcement may impact the company’s shareholder structure and market perception.
Osteopore Ltd. has received Research Governance Office clearance for a clinical study at Princess Alexandra Hospital, focusing on jawbone regeneration using its advanced PCL-TCP scaffold technology. This study aims to address the challenges of current treatments by exploring a regenerative approach that could improve patient outcomes globally, with the first patient recruitment expected in four weeks.
Osteopore Ltd. has announced a significant change in the interests of a substantial holder, Advance Opportunities Fund, which has reduced its voting power in the company. This change involves the indirect sale of shares in the market, affecting the fund’s voting power from 9.96% to 5.55%. This adjustment in shareholding may impact the company’s market dynamics and influence its strategic decisions.
Osteopore Ltd. has announced the recruitment of its first patient in a clinical study at Queensland Children’s Hospital, aiming to treat temporal hollowing in children following cranial vault remodelling surgery. The study will explore the use of a 3D-printed, patient-specific scaffold combined with bone marrow aspirate and platelet-rich fibrin to restore the frontotemporal contour. This initiative underscores Osteopore’s commitment to advancing regenerative medicine solutions, particularly for pediatric patients, and positions the company as a leader in innovative medical technology.
Osteopore Ltd. has announced that Advance Opportunities Fund I has become a substantial holder in the company, acquiring a significant number of fully paid ordinary shares. This acquisition, amounting to 24,096,385 shares and representing an 11.63% voting power, was completed with a consideration of A$200,000. The involvement of Advance Opportunities Fund I as a substantial holder could potentially impact Osteopore’s market position and shareholder dynamics, reflecting increased investor interest and confidence in the company’s prospects.
Osteopore Ltd. has announced the quotation of 24,096,385 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 14, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially strengthening its position in the medical technology sector and offering new opportunities for stakeholders.
Osteopore Limited has secured market approval in Switzerland for its 3D-printed biomimetic and bioresorbable implants under the EU Medical Device Regulation. This approval, following a successful transition to the MDR and a partnership with Zimmer Biomet, enables Osteopore to strengthen its market presence in Switzerland and across Europe, providing a complete suite of craniofacial products. The approval is expected to enhance Osteopore’s operations and industry positioning, particularly in the European cranial implant market, which is projected to grow significantly.
Osteopore Ltd. has announced a change in substantial holding, with the Advance Opportunities Fund I ceasing to be a substantial holder. This change involves indirect selling in the market, impacting 1,600,000 voting securities with a consideration of A$17,600.00. The announcement reflects a shift in the company’s shareholder structure, which could influence its market dynamics and stakeholder relationships.
Osteopore Ltd. has announced a change in the substantial holding of its shares by the Advance Opportunities Fund I. The fund has reduced its voting power from 7.15% to 6.02% through a series of market transactions. This change in shareholding could impact the company’s market dynamics and investor relations as it reflects a shift in stakeholder interest.
Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, which has reduced its voting power from 8.25% to 7.15% by selling 2,000,000 shares. This adjustment in shareholding could impact the company’s market dynamics and stakeholder interests, reflecting a shift in investment strategy by a significant shareholder.
Osteopore Ltd. has announced that Advance Opportunities Fund I has become a substantial holder in the company, acquiring a significant voting power with fully paid ordinary shares. This development indicates a strategic investment move, potentially impacting the company’s market positioning and shareholder dynamics.
Osteopore Ltd. has announced the issuance of 9,615,384 fully paid ordinary securities to be quoted on the ASX, effective June 19, 2025. This move is part of the company’s strategy to enhance its capital structure and support its growth initiatives, potentially strengthening its market position and providing value to its stakeholders.
Osteopore Ltd. has announced that Advance Opportunities Fund I has ceased to be a substantial holder in the company. This change in substantial holding reflects a shift in the voting securities, with the fund selling a significant number of shares, potentially impacting the company’s market dynamics and stakeholder interests.
Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, in its voting securities. The fund has reduced its stake in Osteopore Ltd. from 6.74% to 5.52% by selling shares in the market, which may impact the company’s shareholder structure and influence in decision-making processes.
Osteopore Ltd. has reported a change in the substantial holding of its shares by Advance Opportunities Fund I. The fund’s voting power has decreased from 7.89% to 6.74%, indicating a reduction in its stake in the company. This change could impact the company’s shareholder dynamics and influence in decision-making processes.
Osteopore Limited has announced a new clinical trial in collaboration with Princess Alexandra Hospital to explore maxillomandibular reconstruction using their polycaprolactone-tricalcium phosphate scaffolds. This trial aims to assess the safety and tolerability of the technique, which could potentially offer a more adaptable and less invasive alternative to current treatments. The trial’s success could enhance Osteopore’s industry positioning and lead to further market approvals, benefiting stakeholders by potentially improving patient outcomes and expanding the company’s clinical applications.
Osteopore Ltd. announced the cessation of Daniel Ow as a director effective May 29, 2025. The notice details his relevant interests in securities, including multiple tranches of performance rights expiring in 2030. This change in directorship could impact the company’s strategic direction and stakeholder confidence, given the significant role directors play in guiding company operations.
Osteopore Limited, a company listed on the Australian Securities Exchange, held its Annual General Meeting on May 30, 2025. During the meeting, all proposed resolutions were passed, including a special resolution for a 10% placement facility, indicating strong shareholder support and potentially enhancing the company’s financial flexibility.
Osteopore Ltd. has announced the issuance of convertible notes, marking a strategic financial move to potentially enhance its capital structure. This issuance may impact the company’s operational capabilities and market positioning by providing additional resources for growth and development, potentially benefiting stakeholders through increased innovation and market reach.
Osteopore Ltd. has issued a Cleansing Notice related to its agreement with Advance Opportunities Fund for the issuance of convertible notes. This notice allows the company to issue shares upon conversion of these notes without further disclosure, facilitating retail investment. The agreement involves a subscription amount of up to $20 million, with the latest tranche amounting to $500,000. This strategic financial move is expected to enhance Osteopore’s operational capabilities and market positioning by securing necessary funding for its ongoing projects.
Osteopore Limited has announced a further drawdown of Tranche 1 of their redeemable convertible notes, with subscribers investing an additional A$500,000 in two equal sub-tranches. The funds raised will be used for the company’s ordinary business activities and potential future developments, projects, and investments. This strategic financial move supports Osteopore’s ongoing operations and growth in the regenerative medicine industry, potentially enhancing its market position and offering opportunities for stakeholders.
Osteopore Limited, in collaboration with Queensland Children’s Hospital, has initiated a clinical trial to treat temporal hollowing in children post-cranial vault remodelling surgery for craniosynostosis. This trial, which employs a 3D-printed, patient-specific polycaprolactone-tricalcium phosphate onlay scaffold, aims to assess its feasibility in restoring frontotemporal contour, potentially offering a less invasive alternative to current methods. The study has received ethical clearance and is supported by Maddox’s Helping Hand Foundation, highlighting its potential impact on improving surgical outcomes for young patients.
Osteopore Ltd. has issued a Cleansing Notice regarding the issuance of Third Convertible Notes, part of a subscription agreement with Advance Opportunities Fund. This agreement involves a subsequent investment of $500,000, allowing the company to issue shares without further disclosure to retail investors. The issuance of these convertible notes is expected to impact the company’s financial position and market operations, enhancing its ability to raise capital and expand its market presence.
Osteopore Limited has announced a further drawdown of Tranche 1 of its redeemable convertible notes, with subscribers committing to an additional A$500,000, bringing the total to A$3,500,000 out of a possible A$5,000,000 for this tranche. The funds raised will be used for the company’s ordinary business operations and future development projects, potentially enhancing Osteopore’s market positioning in the regenerative medicine industry.
Osteopore Ltd. has announced a change in the director’s interest, specifically involving Mark Leong. The notice details the various classes of securities and options held by the director, both directly and indirectly, as of May 7, 2025. This change in director’s interest is a routine disclosure that may impact the company’s governance and transparency, providing stakeholders with updated information on the director’s financial interests in the company.